Logo

SLXNW

Silexion Therapeutics Ltd.

SLXNW

Silexion Therapeutics Ltd. • NASDAQ
$0.03 ▲ 0.33% (+0.00)
Market Cap $16941
52w High $0.03
52w Low $0.03
Dividend Yield 0%
P/E 0
Volume 500
Outstanding Shares 560.96K

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $3.288M ▲ $-3.262M ▼ 0% $2.88 ▲ $-3.258M ▼
Q2-2025 $0 $2.284M ▲ $-2.503M ▼ 0% $-4.32 ▼ $-2.497M ▼
Q1-2025 $0 $1.65M ▼ $-1.735M ▲ 0% $0.26 ▲ $-1.722M ▲
Q4-2024 $0 $1.9M ▼ $-1.747M ▲ 0% $-2.7 ▲ $-5.843M ▲
Q3-2024 $0 $8.036M $-11.851M 0% $-18.31 $-11.784M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $9.243M ▲ $11.614M ▲ $4.637M ▼ $6.977M ▲
Q2-2025 $3.466M ▼ $5.797M ▼ $5.677M ▼ $120K ▼
Q1-2025 $6.152M ▲ $8.308M ▲ $5.722M ▼ $2.586M ▲
Q4-2024 $1.222M ▼ $2.863M ▼ $6.852M ▼ $-3.989M ▲
Q3-2024 $1.973M $3.087M $7.666M $-4.579M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-3.262M ▼ $-2.843M ▼ $0 ▲ $8.624M ▲ $5.778M ▲ $-2.843M ▼
Q2-2025 $-2.503M ▼ $-2.507M ▼ $-1K ▲ $-195K ▼ $-2.689M ▼ $-2.508M ▼
Q1-2025 $-1.735M ▲ $-2.453M ▲ $-6K ▼ $7.432M ▲ $4.963M ▲ $-2.459M ▲
Q4-2024 $-1.747M ▲ $-2.926M ▼ $0 ▲ $2.184M ▼ $-753K ▼ $-2.926M ▼
Q3-2024 $-11.86M $-2.653M $-16K $2.92M $276K $-2.669M

Five-Year Company Overview

Income Statement

Income Statement Silexion is essentially a pure research-stage biotech from a financial standpoint. It has no product sales yet and only modest operating expenses showing up so far, which means reported losses are currently small but will likely grow as trials ramp up. The unusual earnings-per-share pattern looks more like an accounting or share-count effect around the IPO than a reflection of real business strength. In practical terms, the company is still in the phase where scientific progress matters far more than its current income statement.

Balance Sheet

Balance Sheet The balance sheet is very light, reflecting a small company that has only recently listed. Assets and cash were minimal before the IPO, and there is no meaningful debt, which reduces financial strain but also highlights the need for ongoing external funding. Equity has swung from slightly negative to roughly break-even over recent years, which is common for young biotechs adjusting capital structure before and after going public. Future capital raises and partnership deals are likely to be the main drivers of balance sheet strength from here.

Cash Flow

Cash Flow Cash flow is negative from operations, with no offsetting revenue and almost no capital spending, which is typical for an early-stage drug developer. The business is consuming cash to fund research and corporate setup rather than generating it. This means the company’s future depends heavily on its ability to regularly access capital markets or partners to support multi-year clinical trials. Investors should expect cash burn to increase as SIL204 and other programs move into more advanced, more expensive stages of development.

Competitive Edge

Competitive Edge Scientifically, Silexion is positioned in an attractive but fiercely competitive area: KRAS-driven cancers. Its angle is differentiated—using RNA interference to shut down KRAS at the mRNA level, rather than just blocking one specific mutant protein. The proprietary LODER delivery system and the dual local-plus-systemic dosing concept create a distinctive package versus traditional small-molecule inhibitors. However, it faces competition from large pharma companies already on the market with KRAS drugs, as well as other RNA-based players, and its lead program still needs strong clinical data to convert this scientific promise into a durable competitive position.

Innovation and R&D

Innovation and R&D Innovation is the main strength here. The company has built a platform around siRNA and localized delivery, with prior clinical proof-of-concept from an earlier-generation product and a more advanced, pan-KRAS candidate now in focus. The LODER system, the dual-route administration strategy, and the broad potential across several major solid tumors all point to a rich R&D story. At the same time, nearly all of the value is tied to future trial results and regulatory outcomes, which are inherently uncertain and typically take many years to crystallize.

Summary

Silexion is a classic clinical-stage biotech: no revenues yet, modest but rising losses, light assets, and reliance on external funding. Its real value proposition is scientific, not financial at this stage. The company’s RNAi-based, pan-KRAS approach with a proprietary delivery technology gives it a clearly differentiated profile in a high-need area of oncology, but it is still early, with pivotal data several years away. The key things to watch are trial progress for SIL204, expansion into additional KRAS-driven cancers, and how effectively the company manages its cash needs and partnerships while navigating the long, risky path through clinical development.